Passage Bio Statistics
Total Valuation
Passage Bio has a market cap or net worth of $10.78 million. The enterprise value is -$13.38 million.
| Market Cap | 10.78M |
| Enterprise Value | -13.38M |
Important Dates
The next estimated earnings date is Monday, November 9, 2026, before market open.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Passage Bio has 3.22 million shares outstanding. The number of shares has increased by 1.12% in one year.
| Current Share Class | 3.22M |
| Shares Outstanding | 3.22M |
| Shares Change (YoY) | +1.12% |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | 0.41% |
| Owned by Institutions (%) | 50.76% |
| Float | 3.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.42 |
| P/TBV Ratio | 2.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.22, with zero debt.
| Current Ratio | 1.22 |
| Quick Ratio | 1.17 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -169.09% and return on invested capital (ROIC) is -70.60%.
| Return on Equity (ROE) | -169.09% |
| Return on Assets (ROA) | -45.62% |
| Return on Invested Capital (ROIC) | -70.60% |
| Return on Capital Employed (ROCE) | -854.82% |
| Weighted Average Cost of Capital (WACC) | 11.92% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.50M |
| Employee Count | 24 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -53.10% in the last 52 weeks. The beta is 1.39, so Passage Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.39 |
| 52-Week Price Change | -53.10% |
| 50-Day Moving Average | 4.34 |
| 200-Day Moving Average | 6.44 |
| Relative Strength Index (RSI) | 33.50 |
| Average Volume (20 Days) | 18,035 |
Short Selling Information
The latest short interest is 68,917, so 2.14% of the outstanding shares have been sold short.
| Short Interest | 68,917 |
| Short Previous Month | 90,840 |
| Short % of Shares Out | 2.14% |
| Short % of Float | 2.15% |
| Short Ratio (days to cover) | 3.35 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -38.09M |
| Pretax Income | -36.11M |
| Net Income | -36.11M |
| EBITDA | -37.58M |
| EBIT | -38.09M |
| Earnings Per Share (EPS) | -$11.31 |
Balance Sheet
The company has $24.16 million in cash and no debt, with a net cash position of $24.16 million or $7.51 per share.
| Cash & Cash Equivalents | 24.16M |
| Total Debt | n/a |
| Net Cash | 24.16M |
| Net Cash Per Share | $7.51 |
| Equity (Book Value) | 4.46M |
| Book Value Per Share | 1.38 |
| Working Capital | 4.46M |
Cash Flow
| Operating Cash Flow | -33.50M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 512,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -33.50M |
| FCF Per Share | -$10.41 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Passage Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.12% |
| Shareholder Yield | -1.12% |
| Earnings Yield | -337.57% |
| FCF Yield | -310.77% |
Analyst Forecast
The average price target for Passage Bio is $15.50, which is 362.69% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.50 |
| Price Target Difference | 362.69% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 14, 2025. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jul 14, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |